LifeMD (LFMD) Scheduled to Post Earnings on Thursday

LifeMD (NASDAQ:LFMD) will be posting its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect LifeMD to post earnings of ($0.09) per share for the quarter. LifeMD has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The firm had revenue of $50.66 million during the quarter, compared to analysts’ expectations of $48.47 million. During the same period in the previous year, the business posted ($0.23) earnings per share. On average, analysts expect LifeMD to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

LifeMD Price Performance

Shares of NASDAQ:LFMD traded down $0.07 during mid-day trading on Tuesday, hitting $4.31. 158,892 shares of the company traded hands, compared to its average volume of 729,472. The stock has a 50-day moving average price of $4.83 and a two-hundred day moving average price of $6.67. LifeMD has a 12-month low of $3.99 and a 12-month high of $12.88. The company has a quick ratio of 0.83, a current ratio of 0.87 and a debt-to-equity ratio of 10.83.

Analysts Set New Price Targets

LFMD has been the topic of a number of research analyst reports. B. Riley started coverage on LifeMD in a research note on Friday, August 23rd. They issued a “buy” rating and a $11.00 target price on the stock. KeyCorp decreased their target price on LifeMD from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 price target on shares of LifeMD in a report on Friday, September 20th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, LifeMD has an average rating of “Buy” and a consensus target price of $12.00.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.